Cohort — Style Guide
Cohort
Clinical Trial Recruitment — Style Guide
v0.1 · two surfaces: staff & candidate
Color tokens — staff app
Ink
#0E1320
Mute
#5A6478
Paper
#F7F8FA
Surface
#FFFFFF
Edge
#E5E8EE
Stone
#F1F3F7
Brand (Trial Blue)
#1E5BFF
Brand Deep
#163CB3
Pine (qualified)
#1F7A4D
Amber (review)
#A66B00
Slate (screen-fail)
#5A6478
Brick (risk)
#A1232B
Candidate surface — warmer almond, serif headlines
A 24-week study of an investigational treatment for adults with type 2 diabetes.
Sponsor: Westcoast Therapeutics · IRB approved · run by Crestline Research, Lexington MA
Time
8 in-clinic visits over 24 weeks
Location
Lexington, MA · 3.2 mi from you
Stipend
$50 per visit · up to $400
Compensation
Travel reimbursed
See if I'm eligible
Type ramp
display / sans 36
12 of 30 randomized · 4 over SLA
candidate / serif 28
A study of an investigational therapy
h1 / 22
Protocol DM2-2410 — Recruiting
h2 / 18
Eligibility trace
h3 / 16
Scheduling window
h4 / 13
Internal note
body / 14
The candidate marked "I don't know" on HbA1c last test value. Route to PI review or schedule for screening lab draw.
small / 13
All times in your timezone (PT). Last sync 4 minutes ago.
mono / 13
DM2-2410 · CAND-A91C · 2025-05-24 16:08 PT
Spacing
4
8
12
16
24
32
48
Buttons
Schedule screening visit
Send pre-screen reminder
Mark needs review
Mark screen-fail
Save criterion
Preview pre-screen
Publish protocol page
Form inputs
Protocol number
Indication
Type 2 diabetes mellitus
Atopic dermatitis
Major depressive disorder
Internal note
Candidate works night shifts; prefers Tuesday/Thursday morning screening visits per their voicemail.
Inclusion — must be true to qualify
Exclusion — disqualifies if true
Show this question on the public pre-screen
Allow "I don't know" answer (routes to PI review)
SLA alert if no contact in 48 hours
Auto-publish protocol page on save
Status pills (text-labeled, never color-only)
Inquiry
Pre-screen
Qualified
Needs review
Screen-fail
SLA breach
Alerts & toast
Pre-screen submitted by CAND-A91C 4 minutes ago. Evaluated against eligibility profile v3.
CAND-A91C qualified on all 8 inclusion criteria. No exclusions triggered.
CAND-B12F answered "I don't know" on HbA1c last test value — route to PI review or schedule for lab draw.
SLA breach — 5 candidates have waited more than 48 hours for first contact.
Screening visit confirmed · Tue May 27, 9:30 AM
Eligibility trace (the staff centerpiece)
INC-001 · inclusion
Adult age 18–75
52
INC-002 · inclusion
Diagnosed with type 2 diabetes ≥ 6 months
yes · 3 yrs
INC-003 · inclusion
Most recent HbA1c between 7.0% and 10.5%
"don't know"
EXC-001 · exclusion
History of pancreatitis
no
EXC-002 · exclusion
Currently on GLP-1 agonist therapy
no
Funnel (per protocol)
Inquiries
218
last 30 days
Pre-screened
164
75% of inquiries
Qualified
62
38% of pre-screened
Screened on-site
41
66% of qualified
Randomized
12
30 target
Table
Candidate
Protocol
Status
Pre-screen
SLA
Last touch
CAND-A91C
DM2-2410-A
Qualified
5/24 · 16:08
12h
5/24 · 16:12
CAND-B12F
DM2-2410-A
Needs review
5/24 · 15:51
14h
5/24 · 15:51
CAND-C04A
AD-2503
Pre-screen
5/24 · 12:02
42h
5/22 · 18:00
CAND-D77E
AD-2503
Screen-fail
5/23 · 09:18
—
5/23 · 11:40
Empty state
No candidates in this column yet
When a candidate's pre-screen evaluates as Qualified, they appear here. The next action is to schedule their screening visit.